Skip to main content
| Hans-Günter Meyer-Thompson | Monatliche Neuheiten

Gilead pays $40m to settle allegations that it delayed work on an improved HIV drug to maximise profits from an older drug 

Gilead pays $40m to settle allegations that it delayed work on an improved HIV drug to maximise profits from an older drug 

Dyer O. 

BMJ 2024; 385 :q1285 doi:10.1136/bmj.q1285 

Abstract

https://www.bmj.com/content/385/bmj.q1285